DHMEQ

You probably never heard of DHMEQ but probably will he hearing a lot about it in the future.  The initials stand for dehydroxymethylepoxyquinomicin, a powerful recently-discovered inhibitor of NF-kappaB.  You might recall that the nuclear activation factor NF-kappaB plays a central role in the 13^th theory of aging, Programmed Genetic Changes.  Runaway overexpression of NF-kappaB is thought to be a key factor in many maladies of old age, particularly inflammatory diseases like arthritis and cancers.  NF-kappaB is constitutively activated in the majority of cancers and is responsible, in large part, for tumor cell survival, growth and direct activation of anti-apoptotic gene factors.  DHMEQ powerfully blocks expression of NF-kappaB and a host of recent publications suggests that it might be useful as a therapeutic agent for several inflammatory diseases and cancers.  You can find some of these publications using a Google search  here.  DHMEQ is unlike some other inhibitors of NF-kappaB in that it selectively blocks translocation into the cell nucleus rather than blocking its action on specific genes.   Although all experiments to date with rodents suggest that DHMEQ is safe, to my knowledge it is not generally available today either as a supplement or as a proprietary drug.  I would not be surprised to see it becoming available in one or both of those formats soon after human safety is established.  In the interim I remind my readers that no less than 33 dietary substances in my anti-aging firewall related to programmed genetic changes are inhibitors of NF-kappaB.  Selective research studies like this one suggest that certain of the firewall NF-kappaB inhibitor substances like curcumin and resveratrol may be comparably powerful in their anti-cancer activities as DHMEQ.